Screener
G&A at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| License revenue | $463 | $1,163 |
| Operating expenses: | ||
| Research and development | 34,528 | 27,003 |
| General and administrative | 12,468 | 7,337 |
| Total operating expenses | 46,996 | 34,340 |
| Loss from operations | (46,533) | (33,177) |
| Other income/(expense): | ||
| Interest and investment income | 6,265 | 3,791 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's G&A?
- Dianthus Therapeutics (DNTH) reported G&A of $12.47M in Q1 2026.
- How has Dianthus Therapeutics's G&A changed year-over-year?
- Dianthus Therapeutics's G&A increased by 69.9% year-over-year, from $7.34M to $12.47M.
- What is the long-term trend for Dianthus Therapeutics's G&A?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's G&A has grown at a -3.6% compound annual growth rate (CAGR), from $27.93M to $24.99M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Dianthus Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude